Pieris Pharmaceuticals (PIRS) Reaches $5.67 After 4.00% Up Move; Quinn Opportunity Partners Has Lowered Its Rite Aid (RAD) Stake

November 14, 2017 - By Adrian Erickson

Quinn Opportunity Partners Llc decreased Rite Aid Corp (RAD) stake by 11.32% reported in 2017Q2 SEC filing. Quinn Opportunity Partners Llc sold 215,013 shares as Rite Aid Corp (RAD)’s stock declined 41.75%. The Quinn Opportunity Partners Llc holds 1.68M shares with $4.97 million value, down from 1.90M last quarter. Rite Aid Corp now has $1.60 billion valuation. The stock declined 5.36% or $0.09 reaching $1.5 per share. About 9.68M shares traded. Rite Aid Corporation (NYSE:RAD) has declined 55.18% since November 14, 2016 and is downtrending. It has underperformed by 71.88% the S&P500.

The stock of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) is a huge mover today! About 215,149 shares traded. Pieris Pharmaceuticals Inc (NASDAQ:PIRS) has risen 128.81% since November 14, 2016 and is uptrending. It has outperformed by 112.11% the S&P500.The move comes after 9 months positive chart setup for the $253.98M company. It was reported on Nov, 14 by Barchart.com. We have $5.90 PT which if reached, will make NASDAQ:PIRS worth $10.16M more.

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $253.98 million. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. It currently has negative earnings. The Company’s Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Among 6 analysts covering Pieris Pharmaceuticals (NASDAQ:PIRS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Pieris Pharmaceuticals has $10 highest and $7 lowest target. $8.33’s average target is 46.91% above currents $5.67 stock price. Pieris Pharmaceuticals had 13 analyst reports since July 22, 2015 according to SRatingsIntel. TH Capital initiated it with “Buy” rating and $7 target in Wednesday, July 22 report. The rating was maintained by JMP Securities on Wednesday, March 9 with “Market Outperform”. The stock of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) has “Outperform” rating given on Tuesday, July 28 by Oppenheimer. The firm has “Market Outperform” rating given on Wednesday, August 12 by JMP Securities. The company was maintained on Thursday, August 17 by Oppenheimer. H.C. Wainwright initiated it with “Buy” rating and $900 target in Tuesday, May 30 report. As per Wednesday, October 18, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating by Roth Capital given on Friday, August 5. The firm has “Buy” rating by Roth Capital given on Thursday, August 13. H.C. Wainwright maintained the stock with “Buy” rating in Friday, August 11 report.

Analysts await Pieris Pharmaceuticals Inc (NASDAQ:PIRS) to report earnings on March, 28. They expect $-0.20 earnings per share, down 25.00% or $0.04 from last year’s $-0.16 per share. After $-0.16 actual earnings per share reported by Pieris Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 25.00% negative EPS growth.

Investors sentiment decreased to 0.78 in 2017 Q2. Its down 0.46, from 1.24 in 2017Q1. It dropped, as 85 investors sold RAD shares while 96 reduced holdings. 50 funds opened positions while 91 raised stakes. 539.25 million shares or 5.01% less from 567.71 million shares in 2017Q1 were reported. Moors Cabot accumulated 26,200 shares or 0.01% of the stock. Kingstown Capital Mgmt LP owns 0.59% invested in Rite Aid Corporation (NYSE:RAD) for 2.00 million shares. Gabelli Advisers has invested 0.59% in Rite Aid Corporation (NYSE:RAD). Alyeska Lp reported 0.1% stake. Peak6 Investments Limited Partnership holds 587,461 shares. Point72 Asia (Hong Kong) Limited reported 77,412 shares. Susquehanna Gp Ltd Liability Partnership holds 0.01% or 7.01 million shares. Gsa Capital Ptnrs Ltd Liability Partnership holds 0.01% or 29,657 shares. Moreover, Dc Advisors has 0.41% invested in Rite Aid Corporation (NYSE:RAD). Vanguard Group Inc stated it has 0.01% in Rite Aid Corporation (NYSE:RAD). Burt Wealth Advsrs invested in 0% or 2,050 shares. First Manhattan Co holds 0% or 1,000 shares. Shikiar Asset Mgmt Inc owns 12,000 shares. Longfellow Invest Mngmt Ltd Liability Corporation reported 1.34M shares stake. Commonwealth Equity Svcs reported 209,695 shares.

Quinn Opportunity Partners Llc increased Comcast Corp (NASDAQ:CMCSA) stake by 24,000 shares to 48,600 valued at $1.89 million in 2017Q2. It also upped General Motors Co (NYSE:GM) stake by 265,000 shares and now owns 680,704 shares. Bank Of America Corp (NYSE:BAC) was raised too.

Among 14 analysts covering Rite Aid (NYSE:RAD), 2 have Buy rating, 2 Sell and 10 Hold. Therefore 14% are positive. Rite Aid had 22 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Mizuho on Friday, October 6 with “Neutral”. The firm has “Buy” rating by Bank of America given on Thursday, August 13. The firm has “Underperform” rating given on Friday, June 30 by Evercore. RBC Capital Markets maintained Rite Aid Corporation (NYSE:RAD) on Wednesday, October 25 with “Hold” rating. The stock has “Hold” rating by Deutsche Bank on Friday, April 8. Vetr downgraded it to “Buy” rating and $9.51 target in Thursday, August 6 report. Evercore downgraded the shares of RAD in report on Wednesday, January 6 to “Hold” rating. The company was upgraded on Friday, August 14 by Vetr. Guggenheim downgraded the shares of RAD in report on Wednesday, April 26 to “Neutral” rating. The firm has “Neutral” rating given on Thursday, July 20 by Mizuho.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>